(Q51919506)

17 April 2018

title

Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). (English)

1 reference

17 April 2018

1 reference

1 reference

Praveen Gupta

1

1 reference

17 April 2018

Sumit Singh

2

1 reference

17 April 2018

Vinay Goyal

3

1 reference

17 April 2018

Garima Shukla

4

1 reference

17 April 2018

Madhuri Behari

5

1 reference

17 April 2018

publication date

1 March 2007

1 reference

17 April 2018

published in

Headache

1 reference

17 April 2018

volume

47

1 reference

17 April 2018

issue

3

1 reference

17 April 2018

page(s)

402-412

1 reference

17 April 2018

The impact of migraine on quality of life in the general population: the GEM study.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Migraine, quality of life, and depression: a population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Features of medication overuse headache following overuse of different acute headache drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Topiramate in migraine prevention: results of a large controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Topiramate for migraine prevention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Topiramate in migraine prevention: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Topiramate in the Treatment of Chronic Migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Symptoms of depression and anxiety, and screening for mental disorders in migrainous patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Preventing disturbing migraine aura with lamotrigine: an open study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Global trends in migraine care: results from the MAZE survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2006.00599.X

Anticonvulsant drugs for migraine prophylaxis

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD003226.PUB2

Identifiers

DOI

10.1111/J.1526-4610.2006.00599.X

1 reference

17 April 2018

PubMed ID

17371357

1 reference

17 April 2018